Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents

(2016) Jordan Axelrad et al.   Clinical Gastroenterology and Hepatology

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis

(2016) Silvia Minozzi et al.   Expert Opinion On Drug Safety

Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review

(2015) Colum Downey   International Journal of Rheumatic Diseases

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

(2014) Louise K Mercer et al.   ANNALS OF THE RHEUMATIC DISEASES

Análise sistemática da influência do antifator de necrose tumoral [anti-TNF] sobre as taxas de infecção em pacientes com artrite reumatoide

(2014) Leslie Goh et al.   Revista Brasileira De Reumatologia

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

(2013) R Landewé et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study

(2013) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

(2013) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial

(2013) Feng Huang et al.   ANNALS OF THE RHEUMATIC DISEASES

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

(2012) Jacqueline Detert et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register

(2012) James B Galloway et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX

(2012) E. Choy et al.   RHEUMATOLOGY

Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide

(2012) Licia Maria Henrique da Mota et al.   Revista Brasileira De Reumatologia

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis

(2009) Der-Yuan Chen et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

(2008) R Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

(2008) J P Leombruno et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis

(2008) Victoria Bejarano et al.   ARTHRITIS AND RHEUMATISM

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

(2008) Alberto Alonso-Ruiz et al.   BMC MUSCULOSKELETAL DISORDERS

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

(2008) Nobuyuki Miyasaka et al.   Modern Rheumatology

Anti-TNF agents for rheumatoid arthritis

(2003) H. E. Seymour et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY